ClinicalTrials.gg
CompletedNCT03944057MARCHUpdated Jun 15, 2023Results posted

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

A Phase 2 interventional study of ATG-010 in Relapse/Refractory Multiple Myeloma, sponsored by Antengene Corporation. Completed at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-15.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Antengene Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing selinexor in Multiple Myeloma — 12 open to participants now, 21 under way, 3 of them phase 3. selinexor · Multiple Myeloma.

Enrollment
10th of 38
82 · median 45
Started
2019
with 1 other
Phase 2
19 of 38
6 open now
Registered
13th of 38
by date
Lead sponsor
1 of 38
Antengene Corporation

Among the 38 studies testing selinexor in Multiple Myeloma, this one is the 10th largest by enrollment, is one of 2 that started in 2019, is one of 19 in phase 2, and was the 13th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 38 studies testing selinexor in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About selinexor

selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing selinexor in Multiple Myeloma, or all of them as a file.
02

Study summary

This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with immunomodulatory agents and proteasome Inhibitors.

Read the detailed description

This is a single-arm, open-label, multicenter study of ATG-010 (Selinexor) plus low dose Dexamethasone dosed twice weekly each week in four-week cycles, in patients with triple-refractory MM. The population refractory for the primary efficacy analysis will contain only patients with triple-MM enrolled. PK analysis would be performed which would contain approximately 30% of the patients enrolled. Safety analyses will be performed on the overall population of patients who received at least one dose of study drug among triple-refractory patient populations. Patients will receive treatment until progressive disease (PD), death, toxicity that cannot be managed by standard care, or withdrawal, whichever occurs first.

03

Conditions studied

  • Relapse/Refractory Multiple Myeloma

Browse trials for

04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 82 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Antengene Corporation is the lead sponsor of 6 studies on the registry; none are open to participants now.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written in accordance with federal, local, and institutional guidelines.
  2. Age ≥ 18 years at the time of signing informed consent.
  3. Patients must have previously received including proteasome inhibitors (PI) (i.e., lenalidomide) and immunomodulatory drugs (i.e., bortezomib) and were to both drugs.
  4. Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #17) that patients experienced from treatments in previous clinical studies must have resolved to Grade ≤ 2 by Cycle 1 Day 1.
  5. Adequate hepatic function within 21 days prior to Cycle 1 Day 1: total \< 2x (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of \< 3x ULN), \< 2.5x ULN and ALT \< 2.5x ULN.
  6. Adequate renal function within 21 days prior to Cycle 1 Day 1: estimated of ≥ 20 mL/min, calculated using the formula of cockroft and gault.
  7. (ECOG) Performance Status of ≤ 2.
  8. Measurable MM based on IMWG guidelines.
  9. Adequate hematopoietic function within 21 days prior to Cycle 1 Day 1 (See Exclusion Criterion #20 for transfusion for RBCs and ):

    1. level ≥ 8.5 g/dL
    2. ≥ 1000/mm\^3
    3. Platelet count ≥ 75,000/mm\^3 (patients in whom \< 50% of bone marrow nucleated cells are plasma cells) or ≥ 50,000/mm\^3 (patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells. [Platelet transfusions \< 1 week prior to Cycle 1 Day 1 are prohibited (see below).]
  10. Female subjects of must have both of the following:

    1. Agree to the use of two study physician-approved methods simultaneously, or practice complete abstinence starting at the time of ICF signature, while on study medication, and 3 months following the last dose of study drug.
    2. Have negative serum pregnancy test result at screening.

Exclusion criteria

Exclusion Criteria:

  • The presence of any of the following will exclude a subject from enrollment:

    1. Active smoldering MM.
    2. Active plasma cell leukemia.
    3. Documented systemic amyloid light chain amyloidosis.
    4. Active central nervous system (CNS) MM.
    5. Pregnancy or breastfeeding.
    6. Chemotherapy ≤ 4 week, radiation and immunotherapy ≤ 4 weeks prior to Cycle 1 Day 1, and radio-immunotherapy 6 weeks prior to Cycle 1 Day 1.
    7. Active graft vs. host disease (after stem cell transplantation) at Cycle 1 Day 1
    8. of \< 4 months.
    9. Major surgery within four weeks prior to Cycle 1 Day 1.
    10. Active, unstable cardiovascular function:

      1. Symptomatic ischemia, or
      2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or
      3. Congestive heart failure (CHF) of (NYHA) Class ≥ 3, or
      4. Myocardial infarction (MI) within 3 months prior to Cycle 1 Day 1.
    11. Prior exposure to a SINE compound, including ATG-010.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    ATG-010 + Dexamethasone

    Open-label ATG-010 80mg plus Dexamethasone 20 mg

    Drug: ATG-010

Interventions

  • ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle). Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)

    Also known as: Selinexor

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    The primary efficacy endpoint of ORR consists of proportion of patients who achieve PR, VGPR, CR, or sCR according to IMWG 2016 criteria: * CR means Negative IFE of serum and urine, disappearance of any soft tissue plasmacytomas (SPD), and \<5% plasma cells in bone marrow aspirates; * sCR means CR as defined above plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry (κ/λ ratio ≤ 4:1 or ≥ 1:2 for κ and λ patients, respectively, after counting ≥ 100 plasma cells); * VGPR means Serum and urine M-protein detectable by IFE but not on electrophoresis, or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours; * PR means ≥50% reduction of serum M-protein plus reduction in 24-hour urine M-protein by ≥90% or to \<200 mg per 24 hours. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.

    Time frame: 12 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    To evaluate progression-free survival

    Time frame: 12 months

08

Results

Posted Jun 15, 2023

Participant flow

Participant flow — Overall Study
MilestoneATG-010 + Dexamethasone
Started82
Completed82
Not completed0

Outcome measures

PrimaryOverall Response Rate (ORR)

The primary efficacy endpoint of ORR consists of proportion of patients who achieve PR, VGPR, CR, or sCR according to IMWG 2016 criteria: * CR means Negative IFE of serum and urine, disappearance of any soft tissue plasmacytomas (SPD), and \<5% plasma cells in bone marrow aspirates; * sCR means CR as defined above plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry (κ/λ ratio ≤ 4:1 or ≥ 1:2 for κ and λ patients, respectively, after counting ≥ 100 plasma cells); * VGPR means Serum and urine M-protein detectable by IFE but not on electrophoresis, or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours; * PR means ≥50% reduction of serum M-protein plus reduction in 24-hour urine M-protein by ≥90% or to \<200 mg per 24 hours. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.

Time frame:
12 months
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsATG-010 + Dexamethasone
Overall Response Rate (ORR)24
SecondaryProgression-Free Survival (PFS)

To evaluate progression-free survival

Time frame:
12 months
Reported as:
Median · month
Progression-Free Survival (PFS)
monthATG-010 + Dexamethasone
Progression-Free Survival (PFS)3.7 (2.02 to 4.66)

Adverse events

Collected over From study drug dosed to 30 days after last study drug dose. SAE was collected from consent. The period is at least no less than 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATG-010 + Dexamethasone7/82 (8.5%)45/82 (54.9%)82/82 (100%)
Most frequent serious events
Most frequent serious events
EventATG-010 + Dexamethasone
PeumoniaInfections and infestations12/82
Platelet count dicreasedInvestigations12/82
Upper respiratory infectionInfections and infestations4/82
AnemiaBlood and lymphatic system disorders4/82
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/82
White blood cell count decreasedInvestigations2/82
Neutrophil count decreasedInvestigations2/82
HyponatremiaMetabolism and nutrition disorders2/82
HypokalemiaMetabolism and nutrition disorders2/82
VomitingGastrointestinal disorders2/82
Most frequent other events
Showing 10 of 58
Most frequent other events
EventATG-010 + Dexamethasone
Decreased platelet countInvestigations72/82
AnemiaBlood and lymphatic system disorders71/82
Decreased white-cell countInvestigations68/82
NauseaGastrointestinal disorders64/82
Lymphocyte count decreasedInvestigations63/82
Neutrophil count decreasedInvestigations59/82
HyponatremiaMetabolism and nutrition disorders56/82
Weight lossInvestigations54/82
Decreased appetiteMetabolism and nutrition disorders51/82
AdynamiaGeneral disorders49/82

Baseline characteristics

Age, Continuous
Age, Continuous(years)ATG-010 + Dexamethasone
Mean61 ± 8.85
Sex: Female, Male
Sex: Female, Male(Participants)ATG-010 + Dexamethasone
Female39
Male43
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ATG-010 + Dexamethasone
Asian82
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)ATG-010 + Dexamethasone
Mean23 ± 3.29
09

Study locations

17 sites
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, Beijing 100020, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510000, China
  • Nanfang Hospital
    Guangzhou, Guangdong 510515, China
  • Sun Yat-Sen University Cancer Center
    Guanzhou, Guangdong 510060, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
  • The Third Xiangya Hospital of Central Suoth University
    Changsha, Hunan 410013, China
  • The First Affilate Hospital with Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • Shanghai Changzheng Hospital
    Shanghai, Shanghai 200003, China
  • Shanghai Sixth People's Hospital Affiliate Shanghai JiaoTong University
    Shanghai, Shanghai 200233, China
  • Xijing Hospital
    Xi'an, Shanxi 710032, China
  • Tianjin blood research institute
    Tianjin, Tianjin 300020, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
10

References and documents

Publications

  • Qiu L, Xia Z, Fu C, Chen W, Chang C, Fang B, An G, Wei Y, Cai Z, Gao S, Weng J, Chen L, Jing H, Li F, Liu Z, Chen X, Liu J, Wang A, Yu Y, Xiang W, Lynch K, Yu Z, Fu W. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. BMC Med. 2022 Apr 5;20(1):108. doi: 10.1186/s12916-022-02305-4. PubMed 35379237 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Feb 2022, 29 months.

Results were first posted in Jun 2023, 1 year 3 months after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 29 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2019
First posted
May 9, 2019
StartActual
Sep 2, 2019
Primary completionActual
Feb 25, 2022
CompletionActual
Feb 25, 2022
Results first posted
Jun 15, 2023
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03944057
Lead sponsor
Antengene Corporation
Responsible party
Sponsor
First posted
May 9, 2019
Start date
Sep 2, 2019
Primary completion
Feb 25, 2022
Completion
Feb 25, 2022
Results posted
Jun 15, 2023
Last update
Jun 15, 2023

Study contacts

Ying Jiao, MD
study director · Medical Monitor

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion